The major randomized trial on the role of IL-1β inhibition in atherosclerosis, CANTOS, reported a significant reduction in the number of incident cases of lung cancer in patients treated with anti-IL-1β antibody compared to placebo-treated patients27. This evidence concerns the gene IL1B and lung carcinoma.